MA34547B1 - Traitement d'association pour traiter une infection par le vhc - Google Patents

Traitement d'association pour traiter une infection par le vhc

Info

Publication number
MA34547B1
MA34547B1 MA35772A MA35772A MA34547B1 MA 34547 B1 MA34547 B1 MA 34547B1 MA 35772 A MA35772 A MA 35772A MA 35772 A MA35772 A MA 35772A MA 34547 B1 MA34547 B1 MA 34547B1
Authority
MA
Morocco
Prior art keywords
hcv infection
treating hcv
association treatment
association
treatment
Prior art date
Application number
MA35772A
Other languages
English (en)
Inventor
Wulf Boecher
Carla Haefner
George Kukolj
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44735903&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34547(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA34547B1 publication Critical patent/MA34547B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des combinaisons thérapeutiques comprenant (a) le composé (1) ou un sel pharmaceutiquement acceptable dudit composé, tel que défini dans les présentes, (b) le composé (2) ou un sel pharmaceutiquement acceptable dudit composé, tel que défini dans les présentes, et éventuellement (c) de la ribavirine. L'invention concerne également des procédés d'utilisation desdites combinaisons thérapeutiques pour traiter une infection par le VHC ou en atténuer un ou plusieurs symptômes chez un patient.
MA35772A 2010-09-30 2011-09-23 Traitement d'association pour traiter une infection par le vhc MA34547B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38825310P 2010-09-30 2010-09-30
PCT/EP2011/066567 WO2012041771A1 (fr) 2010-09-30 2011-09-23 Thérapie combinée pour le traitement d'une infection par le vhc

Publications (1)

Publication Number Publication Date
MA34547B1 true MA34547B1 (fr) 2013-09-02

Family

ID=44735903

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35772A MA34547B1 (fr) 2010-09-30 2011-09-23 Traitement d'association pour traiter une infection par le vhc

Country Status (21)

Country Link
US (1) US20120135949A1 (fr)
EP (1) EP2621495A1 (fr)
JP (1) JP2013540112A (fr)
KR (1) KR20130116245A (fr)
CN (1) CN103228278A (fr)
AP (1) AP2013006734A0 (fr)
AU (1) AU2011310761A1 (fr)
BR (1) BR112013007423A2 (fr)
CA (1) CA2813093A1 (fr)
CL (1) CL2013000670A1 (fr)
CO (1) CO6700843A2 (fr)
EA (1) EA201300421A1 (fr)
EC (1) ECSP13012551A (fr)
MA (1) MA34547B1 (fr)
MX (1) MX2013003060A (fr)
PE (1) PE20131397A1 (fr)
PH (1) PH12013500559A1 (fr)
SG (1) SG188238A1 (fr)
TW (1) TW201306839A (fr)
WO (1) WO2012041771A1 (fr)
ZA (1) ZA201300992B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009293493B2 (en) * 2008-09-17 2014-09-18 Boehringer Ingelheim International Gmbh Combination of HCV NS3 protease inhibitor with interferon and ribavirin
KR20120106942A (ko) 2009-10-30 2012-09-27 베링거 인겔하임 인터내셔날 게엠베하 Ｂｉ２０１３３５, 인터페론 알파 및 리바비린을 포함하는 ｈｃｖ 병용 치료요법을 위한 투여 용법
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
DE112012003510T5 (de) * 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
WO2013147749A1 (fr) * 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Polythérapie orale pour le traitement d'une infection au vhc dans des populations de sous-génotypes de patients spécifiques
WO2013147750A1 (fr) * 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Polythérapie orale pour le traitement d'une infection au vhc dans une sous-population de patients spécifiques
WO2014138374A1 (fr) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Polythérapie par voie orale pour le traitement d'une infection par le vhc chez une sous-population spécifique de patients
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10006A (en) * 1853-09-06 Improvement in printer s ink
US7027A (en) * 1850-01-15 Circulak
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US5767097A (en) 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6277830B1 (en) 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
EP2335700A1 (fr) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de la polymerase du virus hepatitis C avec une structure heterobicylic
ATE422895T1 (de) * 2003-04-16 2009-03-15 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
CL2004001161A1 (es) * 2003-05-21 2005-04-08 Boehringer Ingelheim Int Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
BRPI0413234A (pt) * 2003-08-01 2006-10-03 Genelabs Tech Inc derivados de imidazola bicìclica contra flaviviridae
CN1922174A (zh) * 2004-02-20 2007-02-28 贝林格尔·英格海姆国际有限公司 病毒聚合酶抑制剂
EP1753775B1 (fr) * 2004-05-25 2012-12-26 Boehringer Ingelheim International GmbH Processus de preparation d'inhibiteurs de protease hcv acyclique
CN103524495A (zh) 2005-02-11 2014-01-22 贝林格尔.英格海姆国际有限公司 2, 3-二取代的吲哚的制备方法
JP2008546802A (ja) * 2005-06-24 2008-12-25 ジェネラブズ テクノロジーズ インコーポレーティッド ウイルスを治療するためのヘテロアリール誘導体
US20070032488A1 (en) * 2005-08-05 2007-02-08 Genelabs Technologies, Inc. 6-Membered aryl and heteroaryl derivatives for treating viruses
MX2008010355A (es) * 2006-02-09 2008-10-31 Schering Corp Combinaciones que comprenden inhibidores de proteasa del virus de la hepatitis c e inhibidores de polimerasa del virus de la hepatitis c, y metodos de tratamiento relacionados con los mismos.
WO2009021121A2 (fr) * 2007-08-08 2009-02-12 Wyeth Identification et caractérisation de variants de réplicon de vhc présentant une sensibilité réduite à une combinaison d'inhibiteurs de polymérase et de protéase, et procédés connexes
AU2009293494B2 (en) * 2008-09-16 2014-04-24 Boehringer Ingelheim International Gmbh Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor
AU2009293493B2 (en) * 2008-09-17 2014-09-18 Boehringer Ingelheim International Gmbh Combination of HCV NS3 protease inhibitor with interferon and ribavirin
TW201023858A (en) * 2008-09-18 2010-07-01 Ortho Mcneil Janssen Pharm Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside
EP2358355B1 (fr) 2008-11-21 2013-11-06 Boehringer Ingelheim International GmbH Composition pharmaceutique d'un inhibiteur puissant du vhc pour une administration orale
PE20120322A1 (es) 2009-07-07 2012-04-14 Boehringer Ingelheim Int Composicion farmaceutica que comprende faldaprevir o una sal del mismo en un vehiculo auto-emulsionante

Also Published As

Publication number Publication date
AU2011310761A1 (en) 2013-02-21
CN103228278A (zh) 2013-07-31
PE20131397A1 (es) 2014-01-04
EA201300421A1 (ru) 2013-08-30
CA2813093A1 (fr) 2012-04-05
AP2013006734A0 (en) 2013-02-28
BR112013007423A2 (pt) 2016-07-12
JP2013540112A (ja) 2013-10-31
SG188238A1 (en) 2013-04-30
ECSP13012551A (es) 2013-06-28
CL2013000670A1 (es) 2013-08-09
TW201306839A (zh) 2013-02-16
MX2013003060A (es) 2013-05-30
WO2012041771A1 (fr) 2012-04-05
PH12013500559A1 (en) 2013-05-06
CO6700843A2 (es) 2013-06-28
ZA201300992B (en) 2014-07-30
US20120135949A1 (en) 2012-05-31
EP2621495A1 (fr) 2013-08-07
KR20130116245A (ko) 2013-10-23

Similar Documents

Publication Publication Date Title
MA33076B1 (fr) Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer
EA201200890A1 (ru) Комбинированная терапия hcv
UA105556C2 (uk) Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами
MA33731B1 (fr) Inhibiteurs du virus de l'hépatite c
EA201100505A1 (ru) Органические соединения для применения для лечения бактериальных инфекций
EA201490254A1 (ru) Комбинированное лечение гепатита с
EA200970542A1 (ru) ИНГИБИТОРЫ ДЕЙСТВИЯ Akt
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MA38315B1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
PH12013500559A1 (en) Combination therapy for treating hcv infection
MX2010002735A (es) Envase de titulacion para neramexano y su uso en el tratamiento de un trastorno del oido interno.
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
WO2011035205A3 (fr) Anticorps dirigés contre candida, leurs collectes et procédés d'utilisation
CL2011000571A1 (es) Uso de una combinacion de: a) un compuesto de formula (1) o una sal farmaceuticamente aceptable del mismo, b) interferon alfa y c) ribavirina para preparar un medicamento util para el tratamiento de una infeccion viral de la hepatitis c (hcv) o para aliviar uno o mas sintomas de la misma.
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
EA201170484A1 (ru) Терапевтический режим лечения гепатита, включающий пэг-интерферон, рибавирин и vx-950
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
ATE507214T1 (de) Neuartige serotonin-wiederaufnahmehemmer als arzneimittel mit peripheriesystem-beschränkter aktivität
RU2009122281A (ru) Средство для лечения заболеваний в ветеринарии на основе соли фосфония
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
EA200970127A1 (ru) Модулятор рецепторов глюкокортикостероидов и способы его применения
TW201129361A (en) Methods for treating pain
PT1765360E (pt) Utilizações antivirais de complexos de ácido borínico
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MX2008002456A (es) Uso de ambroxol para el tratamiento de infecciones por rinovirus.